On April 19, Maccura Biotechnology Co., Ltd. released its 2021 annual financial report. The company achieved CNY 3.981 billion revenue in 2021, a year-on-year increase of 7.47%; net profit attributable to shareholders of listed companies was CNY 957 million, a year-on-year increase of 20.49%; basic earnings per share was CNY 1.73. The company plans to distribute a cash dividend of CNY 4.68 (tax included) to all shareholders for every 10 shares. During the reporting period, the sales of COVID-19 related products was CNY 716 million.

Maccura Biotechnology Co., Ltd. revealed that the company has established and implemented the industrial layout of the entire product line. At this stage, the company has ushered in a period of rapid development of independent products. In 2022, the company will focus on advantageous resources, strengthen integrated innovation, and accelerate the realization of the staged goals of each platform and product. The company not only realizes the continuous iteration of high-quality projects and technologies on the traditional product platform in Chinese market, but also achieves orderly advancement and breakthroughs in the production of high-value products on the new technology platform, becoming an integrated supplier of the global diagnostic industry.

At the same time, facing the development trend of the industry, the company is market-oriented, and proposes the strategic goal of systematic, serialized, automated and autonomous development of the entire product line.

About Maccura

Maccura Biotechnology Co., Ltd. is a professional enterprise to research and manufacture clinical IVD products. Maccura was founded in 1994 and has been focusing on the research, manufacture, marketing, and services of IVD products.

Maccura is a hi-tech enterprise certified by related national departments and has passed not only the certification of CMD ISO13485, CQC ISO14001, TUV ISO13485, but also the CE certification for some products.

We have a world-class R&D, manufacture and operation team, have completed the layout of whole industrial chain from biological raw materials, medical laboratory products to professional services, and have the systematic ability to research and manufacture IVD instruments, reagents, calibrators and control materials. Our products have covered platforms of biochemistry, immunoassay, POCT, hematology, molecular diagnosis and pathology, and could meet more than 90% requirements of medical labs with the product integration.

Maccura has become the first Chinese enterprise member of IFCC in 2010, and been certified by CNAS in 2013. In 2015, the reference system department of Maccura has been the first enterprise laboratory in China to enter the JCTLM list and become the cooperation member of IRMM to undertake the assignment for international reference materials.